Akebia Therapeutics, Inc. AKBA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 219.06M | 232.40M | 236.20M | 225.07M | 203.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 219.06M | 232.40M | 236.20M | 225.07M | 203.73M |
| Cost of Revenue | 40.57M | 41.81M | 40.19M | 37.38M | 33.02M |
| Gross Profit | 178.49M | 190.60M | 196.01M | 187.69M | 170.71M |
| SG&A Expenses | 113.79M | 112.17M | 107.48M | 109.07M | 106.49M |
| Depreciation & Amortization | -- | -- | -- | 9.01M | 18.02M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 224.82M | 221.39M | 210.03M | 202.96M | 198.57M |
| Operating Income | -5.76M | 11.01M | 26.17M | 22.12M | 5.16M |
| Income Before Tax | -27.85M | -18.76M | -3.72M | -15.29M | -36.48M |
| Income Tax Expenses | 1.82M | 1.75M | 1.62M | 615.00K | -- |
| Earnings from Continuing Operations | -29.67 | -20.51 | -5.35 | -15.91 | -36.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.67M | -20.51M | -5.35M | -15.91M | -36.48M |
| EBIT | -5.76M | 11.01M | 26.17M | 22.12M | 5.16M |
| EBITDA | -4.21M | 12.29M | 27.44M | 32.41M | 24.51M |
| EPS Basic | -0.11 | -0.08 | -0.02 | -0.08 | -0.17 |
| Normalized Basic EPS | -0.04 | -0.03 | 0.00 | -0.03 | -0.10 |
| EPS Diluted | -0.11 | -0.08 | -0.02 | -0.08 | -0.18 |
| Normalized Diluted EPS | -0.04 | -0.03 | 0.00 | -0.03 | -0.10 |
| Average Basic Shares Outstanding | 1.07B | 1.06B | 1.03B | 981.55M | 927.11M |
| Average Diluted Shares Outstanding | 1.08B | 1.08B | 1.05B | 1.01B | 941.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |